.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,221,786

« Back to Dashboard

Claims for Patent: 8,221,786

Title:Pharmaceutical formulations containing an SGLT2 inhibitor
Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate ##STR00001## and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
Inventor(s): Bindra; Dilbir S. (New Brunswick, NJ), Dali; Mandar V. (New Brunswick, NJ), Parab; Prakash V. (New Brunswick, NJ), Patel; Jatin M. (New Brunswick, NJ), Tao; Li (New Brunswick, NJ), Tejwani; Ravindra W. (New Brunswick, NJ), Vatsaraj; Nipa (New Brunswick, NJ), Wu; Yongmei (New Brunswick, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:12/949,473
Patent Claims: 1. An immediate release pharmaceutical formulation comprising dapagliflozin propylene glycol hydrate and a pharmaceutically acceptable carrier, wherein the dapagliflozin propylene glycol hydrate formulation is in a form selected from the group consisting of a tablet, a stock granulation, and a capsule, wherein the dapagliflozin propylene glycol hydrate is present in an amount to provide a daily dose within the range of from about 0.1 to about 750 mg per day in single or divided doses or multiple doses, which is administered 1 to 4 times, wherein the dapagliflozin propylene glycol hydrate is present in an amount within the range of from 0.1% to 70% of tablet or capsule fill; and the pharmaceutically acceptable carrier comprises: one or more bulking agents/binders in an amount within the range of from 1% to 95% by weight of tablet or capsule fill, the one or more bulking agents/binders comprising one or more of anhydrous lactose in an amount within the range of 0% to 95% by weight of tablet or capsule fill, microcrystalline cellulose in an amount within the range of 0% to 95% by weight of tablet or capsule fill, and pregelatinized starch in an amount within the range of 0 to 95% by weight of tablet or capsule fill; one or more disintegrants in an amount within the range of from 0% to 20% by weight of tablet or capsule fill, the one or more disintegrants comprising one or more of croscarmellose sodium in an amount within the range of 0% to 20% by weight of tablet or capsule fill, crospovidone in an amount within the range of 0% to 12% by weight of tablet or capsule fill, and sodium starch glycolate in an amount within the range of 0% to 20% by weight of tablet or capsule fill; one or more glidants and/or anti-adherents comprising one or more of talc and silicon dioxide in an amount within the range from 0% to 10% by weight of tablet or capsule fill; and one or more lubricants comprising magnesium stearate in an amount within the range of 0.1% to 5% by weight of tablet or capsule fill.

2. The pharmaceutical formulation according to claim 1, wherein the dapagliflozin propylene glycol hydrate is ##STR00018##

3. The formulation as defined in claim 1 in the form of a stock granulation for loading in capsules or forming tablets.

4. The formulation as defined in claim 3 comprising: a) dapagliflozin propylene glycol hydrate, wherein the dapagliflozin propylene glycol hydrate is present in an amount within the range of from about 0.1% to about 30% by weight of tablet or capsule fill; b) bulking agents in a total amount within the range of from about 10% to about 85% by weight of tablet or capsule fill comprising one or more of lactose present in an amount within the range of from about 20% to about 75% by weight of tablet or capsule fill, and microcrystalline cellulose present in an amount within the range of from about 20% to about 75% by weight of tablet or capsule fill; c) a binder comprising pregelatinized starch present in an amount within the range of from about 10% to about 75% by weight of tablet or capsule fill; d) disintegrants in a total amount within the range of from about 2% to about 10% by weight of tablet or capsule fill, comprising one or more of croscarmellose sodium present in an amount within the range of from about 2% to about 10% by weight of tablet or capsule fill, crospovidone present in an amount within the range of from about 4% to about 10% by weight of tablet or capsule fill, and sodium starch glycolate present in an amount within the range of from about 2% to about 10% by weight of tablet or capsule fill; e) one or more glidants and/or anti-adherents comprising talc and/or silicon dioxide, wherein the total amount of glidant and/or anti-adherent is present in an amount within the range of from about 1% to about 10% by weight of tablet or capsule fill; f) a lubricant comprising magnesium stearate present in an amount within the range of from about 0.2% to about 2% by weight of tablet or capsule fill; and g) optionally further comprising an outer protective coating layer comprising a coating polymer and optionally comprising one or more of the following: a plasticizer(s), anti-tacking agent(s), glidant(s), and colorant(s), wherein the total amount of the outer protective coating layer is present in an amount within the range of from about 1% to about 5% by weight of tablet or capsule fill.

5. The formulation as defined in claim 3 in the form of a capsule filled with a stock granulation comprising: a) dapagliflozin propylene glycol hydrate, wherein the dapagliflozin propylene glycol hydrate is present in an amount of 10% by weight of capsule fill; b) microcrystalline cellulose, wherein the microcrystalline cellulose is present in an amount of 68.75% by weight of capsule fill; c) pregelatinized starch, wherein the pregelatinized starch is present in an amount of 15% by weight of capsule fill; d) sodium starch glycolate, wherein the sodium starch glycolate is present in an amount of 3% by weight of capsule fill; e) silicon dioxide, wherein the silicon dioxide is present in an amount of 2% by weight of capsule fill; and f) magnesium stearate, wherein the magnesium stearate is present in an amount of 1.25% by weight of capsule fill.

6. The formulation as defined in claim 3 in the form of a capsule filled with a stock granulation comprising: a) dapagliflozin propylene glycol hydrate, wherein the dapagliflozin propylene glycol hydrate is present in an amount of 22.8% by weight of capsule fill; b) microcrystalline cellulose, wherein the microcrystalline cellulose is present in an amount of 55.95% by weight of capsule fill; c) pregelatinized starch, wherein the pregelatinized starch is present in an amount of 15% by weight of capsule fill; d) sodium starch glycolate, wherein the sodium starch glycolate is present in an amount of 3% by weight of capsule fill; e) silicon dioxide, wherein the silicon dioxide is present in an amount of 2% by weight of capsule fill; and f) magnesium stearate, wherein the magnesium stearate is present in an amount of 1.25% by weight of capsule fill.

7. The formulation as defined in claim 3 in the form of a 2.5 mg dapagliflozin dose tablet comprising: a) dapagliflozin propylene glycol hydrate, wherein the dapagliflozin propylene glycol hydrate is present in an amount of 3.08 mg; b) microcrystalline cellulose, wherein the microcrystalline cellulose is present in an amount of 67.11 mg; c) anhydrous lactose, wherein the anhydrous lactose is present in an amount of 25 mg; d) crospovidone, wherein the crospovidone is present in an amount of 8.75 mg; e) croscarmellose sodium, wherein the croscarmellose sodium is present in an amount of 3.75 mg; f) talc, wherein the talc is present in an amount of 12.5 mg; g) silicon dioxide, wherein the silicon dioxide is present in an amount of 2.88 mg; and h) magnesium stearate, wherein the magnesium stearate is present in an amount of 1.94 mg.

8. The formulation as defined in claim 3 in the form of a 10 mg dapagliflozin dose tablet comprising: a) dapagliflozin propylene glycol hydrate, wherein the dapagliflozin propylene glycol hydrate is present in an amount of 12.3 mg; b) microcrystalline cellulose, wherein the microcrystalline cellulose is present in an amount of 57.89 mg; c) anhydrous lactose, wherein the anhydrous lactose is present in an amount of 25 mg; d) crospovidone, wherein the crospovidone is present in an amount of 8.75 mg; e) croscarmellose sodium, wherein the croscarmellose sodium is present in an amount of 3.75 mg; f) talc, wherein the talc is present in an amount of 12.5 mg; g) silicon dioxide, wherein the silicon dioxide is present in an amount of 2.88 mg; and h) magnesium stearate, wherein the magnesium stearate is present in an amount of 1.94 mg.

9. The formulation as defined in claim 3 in the form of a 50 mg dapagliflozin dose tablet comprising: a) dapagliflozin propylene glycol hydrate, wherein the dapagliflozin propylene glycol hydrate is present in an amount of 61.66 mg; b) microcrystalline cellulose, wherein the microcrystalline cellulose is present in an amount of 114.09 mg; c) anhydrous lactose, wherein the anhydrous lactose is present in an amount of 62.6 mg; d) crospovidone, wherein the crospovidone is present in an amount of 21.91 mg; e) croscarmellose sodium, wherein the croscarmellose sodium is present in an amount of 9.39 mg; f) talc, wherein the talc is present in an amount of 31.3 mg; g) silicon dioxide, wherein the silicon dioxide is present in an amount of 7.2 mg; and h) magnesium stearate, wherein the magnesium stearate is present in an amount of 4.85 mg.

10. The formulation as defined in claim 1, wherein the dapagliflozin propylene glycol hydrate is present in an amount within the range of from about 0.1% to about 30% of the stock granulation; the one or more bulking agents are microcrystalline cellulose and anhydrous lactose, present in an amount within the range of from about 10% to about 85% by weight of the stock granulation; a separate binder is not present; the disintegrant is crospovidone and croscarmellose sodium present in an amount within the range of from about 0.25% to about 10% by weight of the stock granulation; the glidant and/or anti-adherent is talc and silicon dioxide present in an amount within the range from about 1% to about 15% by weight of the stock granulation; and the lubricant is magnesium stearate present in an amount within the range from about 0.2% to about 2% by weight of the stock granulation.

11. An immediate release pharmaceutical formulation comprising dapagliflozin propylene glycol hydrate and a pharmaceutically acceptable carrier, wherein the dapagliflozin propylene glycol hydrate formulation is in a form selected from the group consisting of a tablet, a stock granulation, and a capsule, wherein the dapagliflozin propylene glycol hydrate is present in an amount to provide a daily dose within the range of from about 0.1 to about 750 mg per day in single or divided doses or multiple doses, which is administered 1 to 4 times, in the form of a stock granulation for loading in capsules or forming tablets, the stock granulation comprising: dapagliflozin propylene glycol hydrate is present in an amount within the range of from about 0.1% to about 30% of the stock granulation; one or more bulking agents in an amount within the range of from about 10% to about 85% by weight of the stock granulation; optionally one or more binders in an amount within the range of from about 1% to about 10% by weight of the stock granulation; optionally one or more disintegrants in an amount within the range of from about 0.25% to about 10% by weight of the stock granulation; optionally one or more glidants and/or anti-adherents in an amount within the range from about 1% to about 15% by weight of the stock granulation; and optionally one or more lubricants in an amount within the range from about 0.2% to about 2% by weight of the stock granulation.

12. The formulation as defined in claim 1 in the form of a tablet or capsule, wherein the dapagliflozin propylene glycol hydrate is present in an amount within the range of from 0.1% to 30% of tablet or capsule fill; and the pharmaceutically acceptable carrier comprises: one or more bulking agents/binders in an amount within the range of from 10 to 85% by weight of tablet or capsule fill, the one or more bulking agents/binders comprising one or more of anhydrous lactose in an amount within the range of 20 to 75% by weight of tablet or capsule fill, microcrystalline cellulose in an amount within the range of 20 to 75% by weight of tablet or capsule fill, and pregelatinized starch in an amount within the range of 10 to 75% by weight of tablet or capsule fill; one or more disintegrants in an amount within the range of from 0.25 to 10% by weight of tablet or capsule fill, the one or more disintegrants comprising one or more of croscarmellose sodium in an amount within the range of 2 to 10% by weight of tablet or capsule fill, crospovidone in an amount within the range of 4 to 10% by weight of tablet or capsule fill, and sodium starch glycolate in an amount within the range of 2 to 10% by weight of tablet or capsule fill; one or more glidants and/or anti-adherents comprising one or more of talc and silicon dioxide in an amount within the range from 1 to 4% by weight of tablet or capsule fill; and one or more lubricants comprising magnesium stearate in an amount within the range of 0.2 to 2% by weight of tablet or capsule fill.

13. The formulation as defined in claim 12 in the form of a tablet or capsule, wherein the dapagliflozin propylene glycol hydrate is present in an amount within the range of from 0.1% to 30% of tablet or capsule fill; the one or more bulking agents/binders are anhydrous lactose in an amount within the range of 20% to 75% by weight of tablet or capsule fill, and microcrystalline cellulose in an amount within the range of 20% to 75% by weight of tablet or capsule fill; the one or more disintegrants are croscarmellose sodium in an amount within the range of 2% to 10% by weight of tablet or capsule fill, and crospovidone in an amount within the range of 4% to 10% by weight of tablet or capsule fill; the one or more glidants and/or anti-adherents are talc and silicon dioxide in an amount within the range from 1% to 10% by weight of tablet or capsule fill; and the one or more lubricants are magnesium stearate in an amount within the range of 0.2% to 2% by weight of tablet or capsule fill.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc